Condition: Gastrointestinal Stromal Tumor (GIST) · Gastrointestinal Stromal Cancer · Gastrointestinal Stromal Neoplasm · Sponsor: Kura Oncology, Inc.
In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.
This description comes directly from the study's public registry record.
Kura Medical Information 844-KURAONC · 844-587-2662 · medinfo@kuraoncology.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| Mayo Clinic Cancer Center | Phoenix, Arizona, United States | Recruiting |
| University of California, San Diego | La Jolla, California, United States | Recruiting |
| University of Southern California | Los Angeles, California, United States | Recruiting |
| University Of California, Irvine | Orange, California, United States | Recruiting |
| Stanford Cancer Institute | Palo Alto, California, United States | Recruiting |
| UCLA Santa Monica Medical Center | Santa Monica, California, United States | Recruiting |
| University of Colorado Cancer Center | Aurora, Colorado, United States | Recruiting |
| Sarah Cannon Research Institute | Denver, Colorado, United States | Recruiting |
| Yale University School of Medicine | New Haven, Connecticut, United States | Recruiting |
| Mayo Clinic Cancer Center | Jacksonville, Florida, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
+ 20 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06655246